Compare Amphastar Pharmaceuticals Inc (AMPH) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs AngloGold Ashanti Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.54 (market cap $826.08M), while AngloGold Ashanti Limited trades at $80.02 (market cap $41.51B). The key difference: AngloGold Ashanti Limited is far larger — about 50.2× Amphastar Pharmaceuticals Inc's market cap, and AngloGold Ashanti Limited pays a 5.6% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | AU | |
|---|---|---|
Market Cap | $826.08M | $41.51B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $128.26 |
52-Week Low | $16.87 | $46.25 |
Enterprise Value | $1.22B | $40.64B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
AngloGold Ashanti (AU) trades at $82.10, up 0.23% on the day, with a bearish technical signal but strong fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $2.52 versus $2.27 forecast. The company shows robust revenue growth, with 2025 revenue at $9.89 billion and net income margin of 26.64%. A proposed share repurchase program and a $1.16 dividend for H1 2026 highlight capital returns. Analyst consensus is bullish with a $116.25 price target, though technical indicators suggest near-term resistance.
Outlook remains positive driven by gold price strength and operational efficiency, but risks include geopolitical exposure and commodity volatility. The stock offers value with a P/E of 12.06 and high ROE of 45.39%, yet bearish technical trends and recent earnings misses in Q3 and Q4 2025 warrant caution. Institutional sentiment is mixed, with 64% buy ratings but technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
